stockportfolio.pro
Stocks / CORT vs HALO
CORT vs HALO
Corcept Therapeutics Incorporated and Halozyme Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Corcept Therapeutics Incorporated (CORT) | Halozyme Therapeutics, Inc. (HALO) | |
|---|---|---|
| Market cap | $8.4B | $8.4B |
| Revenue (latest FY) | $761.41M | $1.40B |
| Net income (latest FY) | $98.17M | $316.89M |
| Revenue growth (5y CAGR) | 16.6% | 39.2% |
| Net margin | 12.9% | 22.7% |
| Return on equity | 15.2% | 649.2% |
| P/E ratio | 222.6 | 24.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CORT — free Open HALO — freeFrequently asked questions
Which is bigger, CORT or HALO?
Halozyme Therapeutics, Inc. is larger by market capitalization — $8.4B versus $8.4B.
Which grows faster, CORT or HALO?
Over the last five fiscal years, Halozyme Therapeutics, Inc. grew revenue faster — 39.2%/yr versus 16.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.